HAP Trading’s Mersana Therapeutics MRSN Stock Holding History

HAP Trading’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-880	Closed	-$94K	–	2193
2020 Q4	$94K	Buy	+880	New	+$489K	﹤0.01%	1200

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

HAP Trading's MRSN Position: Q2 2023 in Review

HAP Trading sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 3,583 shares — an estimated $524K sold.

HAP Trading first reported a position in MRSN in Q4 2020 and held it in 2 quarters. The position peaked at $368K in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

HAP Trading reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
HAP Trading sold 3,583 Mersana Therapeutics shares in Q2 2023, an estimated $524K.
HAP Trading first reported a position in Mersana Therapeutics in Q4 2020 and held it in 2 quarters.
HAP Trading's Mersana Therapeutics position peaked at $368K in Q1 2023.
147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on HAP Trading's 13F filing for Q2 2023, filed 11 Aug 2023.